- Home
- IBRX vs BANR Comparison
IBRX vs BANR Comparison
Compare IBRX & BANR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- BANR
- Stock Information
- Founded
- IBRX 2014
- BANR 1890
- Country
- IBRX United States
- BANR United States
- Employees
- IBRX N/A
- BANR N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- BANR Major Banks
- Sector
- IBRX Health Care
- BANR Finance
- Exchange
- IBRX Nasdaq
- BANR Nasdaq
- Market Cap
- IBRX 2.4B
- BANR 2.5B
- IPO Year
- IBRX N/A
- BANR 1995
- Fundamental
- Price
- IBRX $4.49
- BANR $73.52
- Analyst Decision
- IBRX Buy
- BANR Buy
- Analyst Count
- IBRX 2
- BANR 6
- Target Price
- IBRX $17.38
- BANR $61.20
- AVG Volume (30 Days)
- IBRX 10.4M
- BANR 219.5K
- Earning Date
- IBRX 11-12-2024
- BANR 10-16-2024
- Dividend Yield
- IBRX N/A
- BANR 2.61%
- EPS Growth
- IBRX N/A
- BANR N/A
- EPS
- IBRX N/A
- BANR 4.78
- Revenue
- IBRX $7,332,000.00
- BANR $593,391,000.00
- Revenue This Year
- IBRX $1,563.18
- BANR N/A
- Revenue Next Year
- IBRX $1,262.20
- BANR $4.01
- P/E Ratio
- IBRX N/A
- BANR $15.38
- Revenue Growth
- IBRX 1218.71
- BANR N/A
- 52 Week Low
- IBRX $3.10
- BANR $42.00
- 52 Week High
- IBRX $10.53
- BANR $77.01
- Technical
- Relative Strength Index (RSI)
- IBRX 46.07
- BANR 65.44
- Support Level
- IBRX $4.57
- BANR $67.14
- Resistance Level
- IBRX $5.08
- BANR $77.01
- Average True Range (ATR)
- IBRX 0.54
- BANR 2.43
- MACD
- IBRX -0.12
- BANR 0.46
- Stochastic Oscillator
- IBRX 3.16
- BANR 74.24
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.